Related Experiment Video
Updated: Aug 30, 2026
Nanoparticle Delivery of an Oligonucleotide Payload in a Glioblastoma Multiforme Animal Model
Published on: September 27, 2024
Novel chemotherapeutic agents for the treatment of glioblastoma multiforme
Verena Jendrossek1, Claus Belka, Michael Bamberg
1Department of Radiation Oncology, Hoppe-Seyler-Strasse 3, D-72076 Tübingen, Germany. verena.jendrossek@uni-tuebingen.de
Abstract:
During the last few decades, the discovery of novel targets for therapeutic intervention led to the development of chemotherapeutic agents that specifically interfere with altered cellular functions of tumour cells. Genetic alterations in glioblastoma affect cell proliferation and cell cycle control, as well as invasive and metastatic growth. Therefore, innovative therapeutic strategies have been based on drugs targeting cellular proliferation, invasion, angiogenesis, metastasis and differentiation of tumour cells. Furthermore, disruption of cell-death pathways also contributes to the pathogenesis of glioblastoma and may result in resistance to chemotherapy and radiation. Therefore, additional treatment strategies that target intracellular survival and/or apoptotic pathways are under current laboratory investigation. The progress in the understanding of glioblastoma tumour biology and the refined diagnosis of individual patients together with the exploration of targeted drugs may allow a risk-adapted, individualised therapeutic strategy and will hopefully improve prognosis of glioblastoma patients in the future.
Insights
Novel chemotherapeutic agents target glioblastoma's altered cell functions, including proliferation and invasion. Future strategies focus on targeting cell-death and survival pathways to improve patient prognosis.
Area of Science:
- Oncology
- Cancer Biology
- Pharmacology
Background:
- Glioblastoma (GBM) is characterized by genetic alterations affecting cell proliferation, invasion, and metastasis.
- Disruption of cell-death pathways contributes to GBM pathogenesis and can cause resistance to conventional therapies.
- Understanding GBM biology is crucial for developing targeted therapeutic interventions.
Purpose of the Study:
- To review the development of chemotherapeutic agents targeting altered cellular functions in glioblastoma.
- To explore innovative therapeutic strategies for glioblastoma, including targeting proliferation, invasion, angiogenesis, metastasis, and differentiation.
- To highlight the importance of targeting intracellular survival and apoptotic pathways for overcoming treatment resistance.
Main Methods:
- Review of recent advances in glioblastoma research and drug development.
- Analysis of genetic alterations and their impact on tumor cell functions.
- Investigation of novel therapeutic targets and strategies.
Main Results:
- Chemotherapeutic agents have been developed to specifically interfere with tumor cell functions.
- Targeted drugs focus on inhibiting proliferation, invasion, angiogenesis, metastasis, and promoting differentiation.
- Targeting intracellular survival and apoptotic pathways are under investigation to overcome resistance.
Conclusions:
- Advances in understanding glioblastoma biology and diagnosis enable individualized therapeutic strategies.
- Targeted drug exploration holds promise for improving glioblastoma patient prognosis.
- Future research should focus on integrated approaches combining targeted therapies and understanding resistance mechanisms.
